0001493152-26-007105
SEC filingNano Nuclear Energy Inc reported a net loss of $6.5 million for Q1 2026, an improvement from the $11.6 million operating loss due to $5.0 million in other income. The company generated negative operating cash flow of $4.0 million and negative investing cash flow of $3.1 million, but raised $381.3 million from financing activities primarily through $400.0 million in common stock issuances. This resulted in a net cash increase of $374.3 million, ending the period with $203.3 million in cash and equivalents. Total assets grew to $606.1 million, with stockholders' equity at $599.6 million. The company continues to invest heavily in research and development ($5.4 million) and general administrative expenses ($6.9 million) as it develops its nuclear energy technology.
Nano Nuclear Energy Inc reported a net loss of $6.5 million for Q1 2026 (period ending December 31, 2025), which represents an improvement from the $11.6 million loss from operations. This improvement was primarily driven by $5.0 million in other income. The company's comprehensive loss was also $6.5 million, including a cumulative translation adjustment of -$11K. Operating expenses totaled $12.3 million, consisting of $6.9 million in general and administrative expenses and $5.4 million in research and development costs. The company reported a change in fair value of contingent consideration of -$728K. No prior period QoQ comparisons are provided in the data.
No revenue figures are disclosed in the provided financial data. The income statement shows no revenue line items, indicating the company is in a pre-revenue stage of development. The primary financial activities during the period were expense-driven, with significant investments in research and development ($5.4 million) and general administrative functions ($6.9 million). The $5.0 million in other income represents the largest positive contribution to the financial results, though its specific source is not detailed in the provided data.
The company reported negative operating income of $11.6 million, resulting from $12.3 million in operating expenses offset by no disclosed revenue. The net loss of $6.5 million represents a 44% improvement from the operating loss, primarily due to $5.0 million in other income. Additional items affecting profitability included an unrealized loss on marketable securities of -$123K and a gain on settlement of accounts receivable of $153K. The company's cost structure is dominated by research and development ($5.4 million) and general administrative expenses ($6.9 million), reflecting its focus on technology development.
The company used $4.0 million in operating activities and $3.1 million in investing activities during the quarter. Financing activities provided $381.3 million, primarily from $400.0 million in common stock issuances, offset by $21.5 million in offering costs. This resulted in a net cash increase of $374.3 million. The balance sheet shows total assets of $606.1 million, including $577.5 million in cash and cash equivalents, $11.0 million in property, plant and equipment, and $9.1 million in in-process research and development. Total liabilities are $6.5 million, resulting in stockholders' equity of $599.6 million.
No forward-looking guidance, strategic priorities, or specific risk factors are disclosed in the provided financial data. The company's financial position appears strengthened by the $400.0 million raised through common stock issuances, providing substantial liquidity for continued operations and development activities. The significant investments in research and development ($5.4 million) and in-process research and development assets ($9.1 million) suggest ongoing focus on technology development. The company maintains a strong cash position of $203.3 million at period end, which should support continued operations in the near term.